<DOC>
	<DOCNO>NCT01009177</DOCNO>
	<brief_summary>The study design multicenter , double blind , parallel-group , placebo-controlled , randomize , event drive Phase II study DTIC without bosentan first-line treatment patient stage IV melanoma .</brief_summary>
	<brief_title>Effect Bosentan Patients With Metastatic Melanoma Treated With Dacarbazine ( DTIC )</brief_title>
	<detailed_description>This randomize , double-blind ( 1:1 bosentan : placebo ) trial evaluate effect bosentan combination DTIC TTP death patient metastatic melanoma stage IV . The patient receive study medication ( bosentan placebo ) DTIC 35 week 105 week ; study complete 66 event ( tumor progression , death due underlying disease , other/additional anti-tumor therapy ) observe . Study drug administer orally , 500 mg twice day . DTIC give every three week dosage 1000 mg/m2 intravenously ( i.v . ) accordance Institution 's DTIC treatment protocol .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Male female patient 18 year age old 2 . Histologically proven malignant melanoma ( Balch et al. , J. Clin Oncol . 19 ( 16 ) : 363548 , 2001 ) stage IV measurable disease define RECIST criterion ( Therasse et al. , J Natl Cancer Inst , 92 ( 3 ) : 20516 , 2000 ) . 3 . Patients prior radiation therapy ( &gt; 30 day prior study drug initiation ) allow provided indicator lesion ( ) use study ( ) outside field radiation represent new lesion previously irradiate . 4 . Patients prior therapy DTIC . 5 . Patients cutaneous melanoma lesion must consent biopsy obtain screen period end treatment exploratory analysis endothelin receptor expression . Biopsies obtain prior study frozen accordance procedure specify protocol may use . 6 . ECOG performance status ( ≤ 2 ) 7 . Life expectancy &gt; 12 week 8 . Female patient must nonpregnant , nonbreast feeding , either post menopausal , surgically sterile , practice reliable method contraception ( hormonal method alone sufficient ) 9 . Provide write informed consent 10 . Willing return study center follow 1 . ALT and/or AST &gt; 3 × upper limit normal ( ULN ) screening OR ALT /or AST &gt; 2 x ULN total bilirubin &gt; 2.0 mg/dl screen 2 . Lactate dehydrogenase &gt; 1.5 x ULN 3 . Hemoglobin &gt; 30 % low limit normal 4 . Systolic blood pressure &lt; 85 mmHg 5 . NYHA class III/IV congestive heart failure 6 . Any prior chemotherapy , biological therapy immunotherapy stage IV metastatic disease . 7 . Received immunotherapy &lt; 30 day treatment start ( complete adjuvant immunotherapy previous resect metastatic disease allow ) 8 . Concurrent use calcineurin inhibitor ( cyclosporine A , tacrolimus ) , sirolimus , fluconazole glibenclamide ( glyburide ) expect receive drug study inclusion study . 9 . History malignancy last 5 year , exception squamous cell carcinoma skin treat local resection basal cell carcinoma 10 . CNS metastases carcinomatous meningitis 11 . Ocular melanoma 12 . Known hypersensitivity excipients Tracleer™ 13 . Prior therapy bosentan 14 . Use therapy another investigational drug within 4 week start dose bosentan plan receive treatment study 15 . Known drug alcohol dependence factor interfere conduct study 16 . Any standard contraindication use DTIC per Australian package insert</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>DTIC</keyword>
	<keyword>Bosentan</keyword>
</DOC>